T-Cell Lymphoma
T-Cell Lymphoma
The latest news, research, and perspectives in T-cell lymphoma. Most T-cell lymphomas are non-Hodgkin lymphomas that develop from mature T cells. The most common subtypes include mycosis fungoides, anaplastic large-cell lymphoma, and precursor T-lymphoblastic lymphoma.
Leah SherwoodPrint | November 23, 2022
A Biologics License Application was submitted to the FDA by the manufacturer of the drug denileukin diftitox.
Read More
Leah SherwoodT-Cell Lymphoma | October 3, 2022
The use of extracorporeal photopheresis declined in patients with Sézary syndrome as the COVID-19 pandemic began.
Kerri FitzgeraldT-Cell Lymphoma | September 16, 2022
The number of cases of cutaneous T-cell lymphoma continues to increase in the United States.
Kerri FitzgeraldT-Cell Lymphoma | September 16, 2022
There is a knowledge gap about subcutaneous panniculitis-like TCL owing to its rarity and diagnostic difficulty.
Kerri FitzgeraldT-Cell Lymphoma | September 16, 2022
Updated staging and clinical trial guidelines for primary cutaneous lymphomas (PCLs) have been proposed.
Kerri FitzgeraldPrint | September 13, 2022
Dr. Pro discusses the exciting advancements made in lymphoma and what still needs to be done to improve patient outcomes.
Cecilia BrownT-Cell Lymphoma | August 25, 2022
SGX301 is a novel, first-in-class, photodynamic therapy utilizing visible light for activation.
Leah SherwoodT-Cell Lymphoma | August 19, 2022
The single-center trial included adults with R/R multiple myeloma, T-cell lymphoma, or acute myeloid leukemia.
Leah SherwoodT-Cell Lymphoma | August 18, 2022
A pegasparaginase-based chemotherapy regimen showed promising preliminary results when compared to a regimen that was ...
Leah SherwoodT-Cell Lymphoma | August 18, 2022
Cusatuzumab, a CD70-directed monoclonal antibody, had antitumor activity in highly pre-treated patients with CD70-positive ...
Cecilia BrownT-Cell Lymphoma | July 27, 2022
Investigators retrospectively identified patients with PTCL who were treated with romidepsin plus subcutaneous azacitidine.
Leah SherwoodT-Cell Lymphoma | July 27, 2022
Topical synthetic hypericin activated with visible light is an effective and well-tolerated photodynamic therapy (PDT) to ...
Leah SherwoodT-Cell Lymphoma | July 27, 2022
Single-agent nivolumab was associated with modest activity in patients with relapsed or refractory (R/R) peripheral T-cell ...
Leah LawrenceTransplantation & Cellular Therapy | May 31, 2022
Autologous hematopoietic stem cell transplantation improved survival outcomes for certain patients younger than 65.
Leah LawrenceT-Cell Lymphoma | May 10, 2022
The findings raise concern about the state of wellness of the hematology/oncology workforce.
Leah LawrenceT-Cell Lymphoma | April 11, 2022
Researchers inactivated thousands of genes in several adult T-cell leukemia/lymphoma cell lines and found CDK6 to be a ...
Leah LawrenceT-Cell Lymphoma | April 4, 2022
WU-CART-007 is being tested as part of a phase 1/2 trial that will evaluate if use of the off-the-shelf therapy is safe and ...
Sabrina AhleMyeloma | March 22, 2022
New legislation would set time limits around FDA accelerated approvals.
Ariel DeMaioT-Cell Lymphoma | March 7, 2022
Peripheral T-cell lymphomas represent about 10% to 15% of all non-Hodgkin lymphomas.
Sabrina AhleMyeloma | February 22, 2022
Patients with hematologic malignancies have a significantly higher rate of composite thrombotic outcomes during acute ...
Advertisement
Editorial Board

Advertisement